» Articles » PMID: 16271804

Redox Proteomics Identification of Oxidized Proteins in Alzheimer's Disease Hippocampus and Cerebellum: an Approach to Understand Pathological and Biochemical Alterations in AD

Overview
Journal Neurobiol Aging
Publisher Elsevier
Date 2005 Nov 8
PMID 16271804
Citations 131
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is characterized by the presence of neurofibrillary tangles, senile plaques and loss of synapses. There is accumulating evidence that oxidative stress plays an important role in AD pathophysiology. Previous redox proteomics studies from our laboratory on AD inferior parietal lobule led to the identification of oxidatively modified proteins that were consistent with biochemical or pathological alterations in AD. The present study was focused on the identification of specific targets of protein oxidation in AD and control hippocampus and cerebellum using a redox proteomics approach. In AD hippocampus, peptidyl prolyl cis-trans isomerase, phosphoglycerate mutase 1, ubiquitin carboxyl terminal hydrolase 1, dihydropyrimidinase related protein-2 (DRP-2), carbonic anhydrase II, triose phosphate isomerase, alpha-enolase, and gamma-SNAP were identified as significantly oxidized protein with reduced enzyme activities relative to control hippocampus. In addition, no significant excessively oxidized protein spots were identified in cerebellum compared to control, consistent with the lack of pathology in this brain region in AD. The identification of oxidatively modified proteins in AD hippocampus was verified by immunochemical means. The identification of common oxidized proteins in different brain regions of AD brain suggests a potential role for these oxidized proteins and thereby oxidative stress in the pathogenesis of Alzheimer's disease.

Citing Articles

Newer Therapeutic Approaches in Treating Alzheimer's Disease: A Comprehensive Review.

Reddi Sree R, Kalyan M, Anand N, Mani S, Gorantla V, Sakharkar M ACS Omega. 2025; 10(6):5148-5171.

PMID: 39989768 PMC: 11840625. DOI: 10.1021/acsomega.4c05527.


Examining the role of antioxidant supplementation in mitigating oxidative stress markers in Alzheimer's disease: a comprehensive review.

Jawad M, Uthirapathy S, Altalbawy F, Oghenemaro E, Rizaev J, Lal M Inflammopharmacology. 2024; 33(2):573-592.

PMID: 39699843 DOI: 10.1007/s10787-024-01622-9.


Behavioral and Biochemical Effects of an Arylhydrazone Derivative of 5-Methoxyindole-2-Carboxylic Acid in a Scopolamine-Induced Model of Alzheimer's Type Dementia in Rats.

Petkova-Kirova P, Anastassova N, Minchev B, Uzunova D, Grigorova V, Tsvetanova E Molecules. 2024; 29(23).

PMID: 39683869 PMC: 11643547. DOI: 10.3390/molecules29235711.


The Dual Role of Amyloid Beta-Peptide in Oxidative Stress and Inflammation: Unveiling Their Connections in Alzheimer's Disease Etiopathology.

Fanlo-Ucar H, Picon-Pages P, Herrera-Fernandez V, Ill-Raga G, Munoz F Antioxidants (Basel). 2024; 13(10).

PMID: 39456461 PMC: 11505517. DOI: 10.3390/antiox13101208.


Abolishing UCHL1's hydrolase activity exacerbates ischemia-induced axonal injury and functional deficits in mice.

Mi Z, Povysheva N, Rose M, Ma J, Zeh D, Harikumar N J Cereb Blood Flow Metab. 2024; 44(11):1349-1361.

PMID: 38833565 PMC: 11542126. DOI: 10.1177/0271678X241258809.